PMID- 10371346
OWN - NLM
STAT- MEDLINE
DCOM- 19990623
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 84
IP  - 3
DP  - 1999 Jun 21
TI  - c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples.
PG  - 273-7
AB  - We investigated c-erbB-2 oncogene amplification and over-expression in 79 
      invasive breast carcinoma samples using fluorescence in situ hybridization (FISH) 
      and immunohistochemistry, with the aim of studying relationships between 
      neoplasms over-expressing c-erbB-2 with or without amplification and 
      bio-pathological parameters used in clinical breast cancer. Nineteen samples 
      showed amplification, and all of these were positive by immuno-histochemistry. 
      Moderate or intense immunostaining was present in a further 22 samples without 
      c-erbB-2 amplification and was not related to any increased number of c-erbB-2 
      signals: 15 samples exhibited chromosome 17 polysomy, 3 monosomy and 4 no FISH 
      abnormalities. Thirty-eight samples were immunonegative: 18 exhibited chromosome 
      17 polysomy, 9 monosomy and 11 no alterations. Samples having c-erbB-2 
      over-expression associated with amplification showed DNA aneuploidy and hormonal 
      receptor loss to a greater extent than those expressing c-erbB-2 without 
      amplification or immunonegative samples (chi2 test, p = 0.007, 0.008 and 0.008, 
      respectively). The proliferation rate, detected by Ag-NOR staining, was highest 
      in amplified samples (Kruskal Wallis test, p = 0.009). Our results indicate that 
      tumours showing both c-erbB-2 over-expression and amplification exhibit more 
      aggressive biological characteristics than those with only over-expression or 
      immunonegative tumours. Since both c-erbB-2 amplification and over-expression 
      have been related to negative responses to chemotherapy and poor prognosis, these 
      differences might have clinical implications. The combination of FISH and 
      immuno-histochemistry may be helpful to achieve this aim.
FAU - Farabegoli, F
AU  - Farabegoli F
AD  - Department of Experimental Pathology, University of Bologna, Italy. 
      frbfl@kaiser.alma.unibo.it
FAU - Ceccarelli, C
AU  - Ceccarelli C
FAU - Santini, D
AU  - Santini D
FAU - Baldini, N
AU  - Baldini N
FAU - Taffurelli, M
AU  - Taffurelli M
FAU - Marrano, D
AU  - Marrano D
FAU - Trere, D
AU  - Trere D
FAU - Derenzini, M
AU  - Derenzini M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*chemistry/genetics/pathology
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*analysis
EDAT- 1999/06/17 10:00
MHDA- 2000/06/20 09:00
CRDT- 1999/06/17 10:00
PHST- 1999/06/17 10:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/06/17 10:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19990621)84:3<273::AID-IJC13>3.0.CO;2-7 [pii]
AID - 10.1002/(sici)1097-0215(19990621)84:3<273::aid-ijc13>3.0.co;2-7 [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Jun 21;84(3):273-7. doi: 
      10.1002/(sici)1097-0215(19990621)84:3<273::aid-ijc13>3.0.co;2-7.